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Dear Colleagues,
The clinical presentation of fungal disease is strongly determined by the underlying immune
defect present [1]. In particular, over the last two decades, the increased recognition of monogenic
disorders (e.g., primary immunodeficiencies) have provided us with valuable insights into human
immunity to fungal infections. The discovery of those so-called “experiments of nature” have been
crucial in the elucidation of underlying molecular mechanisms with the ultimate aim to develop new
treatment modalities.
Genetic polymorphisms resulting in defects in Candida recognition, Th17 differentiation and
proliferation or IL-17R signalling can increase susceptibility to chronic mucocutaneous candidiasis,
and lend evidence for the importance of the Th17/IL-17axis in antifungal immunity. Mengesha and
Conti describe in this Special Issue the current insights in the molecular pathways involved in
IL-17 mediated antifungal immunity [2]. They also refer to the potential risks of fungal infectious
complications associated with the use of anti-IL-17 antibodies in the treatment of auto-immune diseases.
The current molecular insights, although most likely far from complete, have already resulted in new
therapeutic leads and are currently being investigated [3].
An excellent review written by Heung provides us with a valuable update on the progress made
in deciphering the immune responses and molecular pathways to resist cryptococcal infections [4].
Next to adaptive immune cells, several innate immune cell types appear to have effector functions
to combat cryptococcal disease. In parallel, identification of non-HIV patients with specific immune
defects rendering them susceptible to cryptococcosis have recently been described [5].
Meya et al. demonstrate the results of their study in this Special Issue that monocyte subset
phenotype and cytokine responses prior to antiretroviral therapy may be predictive of cryptococcal
meningitis immune reconstitution inflammatory syndrome (CM-IRIS) [6]. Although the study
population was small, 17 HIV patients of which 11 developed CM-IRIS, the absence of non-classical
monocytes at CM diagnosis and an increased IFNγ induced IL-6 and TNFα expression by monocytes
differentiated those patients developing CM-IRIS. Those new results in combination with previous
clinical and experimental data suggest that immunomodulatory therapy to neutralize and/or suppress
IL-6 and/or TNFα may be an attractive approach to prevent or improve the outcome of CM-IRIS.
Chronic pulmonary aspergillosis is observed in patients with a wide variety of underlying
lung diseases, although no specific immune defects associated with the development of CPA have
been identified. Obviously, the damaged lung tissue by the primary lung disease may facilitate
Aspergillus conidia to persist and germinate into hyphal airway invasive structures, leading to
pulmonary aspergillosis. Since only a subset of patients with a defined underlying lung disease
develops CPA, the following question arises: Do those patients suffer from additional defects in
their immune system? Bongomin et al. have made a first attempt to look into this by analysing
immunophenotyping of lymphocyte subsets in peripheral blood samples of 144 patients with CPA [7].
Interestingly, 12.5% of the patients had a subnormal NK-cell (CD56) count and the role of NK-cells in
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antifungal immunity has been nicely reviewed by Schmidt et al. in this Special Issue [8]. They refer to
two clinical observational studies in post-haematopoietic stem cell and post-solid organ transplantation
patients demonstrating an association with poor function and/or low numbers of NK-cells and the
development of invasive aspergillosis. In both studies, as well as in the study presented by Bongomin
in this Special Issue, it nevertheless remains unclear if the low number of NK-cells caused Aspergillus
disease to develop. The challenge to be aimed for is to perform longitudinal clinical studies in
well-defined patient groups to demonstrate a causative relationship between abnormal lymphocyte
subsets and the development of CPA.
The increased insight in the characteristics of polysaccharides in the fungal cell wall,
its recognition by specific pathogen receptors, and the downstream signalling resulting in either up- or
down-regulation of inflammatory pathways is the subject of the review by Snarr et al. in this Special
Issue [9]. In addition, the authors refer to the promising potential of this new knowledge with respect
to the development of antifungals with a new mode of action and the use of immunosuppressive
fungal polysaccharides in the treatment of inflammatory disorders as rheumatoid arthritis. On the
other hand, Hernandez-Chavez et al. present us with a clearly written overview of how fungal cells
have evolved several strategies to avoid recognition by immune cells, including the modulation of the
amount of certain cell wall components (e.g., polysaccharides) or their accessibility on the fungal cell
surface [10].
The ability of C. albicans to form biofilms on the surfaces of medical and prosthetic devices,
as well as on host epithelial and endothelial layers, is strongly related to a worse outcome [11].
Candida biofilms are notoriously resistant to antifungal therapy and severely compromise effective
antifungal activity by phagocytes. Two papers in this Special Issue focus on specific antifungal immune
mechanisms being impaired when confronted with C. albicans growing in biofilms. Kernien et al.
demonstrate how various clinical C. albicans isolates forming biofilms inhibit the release of neutrophil
extracellular traps (NETs) [12]. This inhibition was shown early in the formation of the biofilm before
the development of long hyphal structures known to result in “frustrated” phagocytosis and release of
NETs. Alonso et al. demonstrated an impaired migration of macrophages towards C. albicans growing
in a biofilm compared to planktonic Candida cells [13]. Mannans in the fungal cell wall and/or
secreted in the extracellular matrix seem to inhibit NET formation [14], while the impaired macrophage
migration is not dependent on the presence of mannans. This is another example of how fungal
polysaccharides play various and sometimes contradictory roles in the host–fungus interaction.
Ongoing exploration and understanding of those immunological pathways is needed to ultimately
lead to new directions in the development of immunotherapeutic strategies to spot the invading fungus
early, leaving it no escape. Novel immunotherapeutic approaches are urgently needed, as the classes
of antifungal drugs are restricted, and, even with the arrival of the newer ones, the prognosis for
patients with fungal infection is still poor. A recent review by Armstrong-James and colleagues show
the progress made in adjunctive antifungal strategies such as cytokine therapy, vaccines, and cellular
immunotherapy [15].
I would like to take the opportunity to express my gratitude to our colleague experts who
contributed to this Special Issue resulting in a collection of excellent papers summarizing current
concepts and understanding as well as the latest insights obtained in the host–fungus interactions.
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